Agenus Inc. (AGEN)
NASDAQ: AGENHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
AGEN stock chart
Technical analysisKey statistics
All statistics- Market cap
- $270.12M
- P/E (TTM)
- 25.96
- EPS (TTM)
- $0.23
- Dividend yield
- None
- 52-week range
- 2.71 – 10.31
- Day range
- 5.90 – 6.26
- Volume / Avg
- 711.70K / 905.17K
- Beta
- —
- Shares outstanding
- 45.25M
52-week range
AGEN stock today
Shares of Agenus (AGEN) finished lower on Nov 20 at $5.97, a drop of 2.77% or $0.17 per share, versus the S&P 500's 3.70% decline. Shares are 42.1% below their 52-week high of $10.31, set on Sep 30, 2026 and 120.3% above the 52-week low of $2.71, in the middle of the past year's range. AGEN is up 90.1% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 41.5%.
Agenus trades at 26.0x its trailing twelve-month earnings per share of $0.23.
Summary generated from market data by MetaCap's automated system. Methodology
About Agenus
Company profileAgenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Dr. Garo H. Armen Ph.D.
- Headquarters
- Lexington, MA
- Employees
- 81
- IPO year
- 2000
- Website
- agenusbio.com
Financial highlights
Full financialsIn fiscal 2025, Agenus generated $114.2 million in revenue, up 10.4% from fiscal 2024. Agenus reported a net loss of $3.1 million, compared with a loss of $232.3 million a year earlier. Gross margin was 99.1% (down from 99.5%) and operating margin -17.7%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $114.20M | $103.46M | $156.31M | $98.02M | $295.67M |
| Growth | +10.37% | -33.81% | +59.47% | -66.85% | +235.34% |
| Net income | $-3.08M | $-232.27M | $-257.44M | $-230.66M | $-28.72M |
| EPS (diluted) | $0.00 | $-10.59 | $-13.75 | $-15.64 | $-0.11 |
Analyst forecast
ForecastConsensus (3 analysts)
strong_buy
Avg. price target
$27.00+352.26%
- Strong buy 0
- Buy 3
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 5, 2026
- EPS actual vs est.
- $0.02 vs $0.02
- Surprise
- 0.00%
AGEN news
All AGEN news- Agenus' Q3 Earnings Match Estimates, Revenues Miss Mark, Stock DownNasdaqAGEN, TGTX, AMRX, IBRX
- Agenus Reports Third Quarter 2026 Results, Highlighted by First Marketing Authorizations for BOT+BAL and Global Investigator Support for Phase 3 ROBBIN StudyBusiness Wire
- Agenus to Provide Third Quarter 2026 Financial Report and Development UpdateBusiness Wire
- ImmunityBio (IBRX) Reports Q2 Loss, Beats Revenue EstimatesNasdaqIBRX, AGEN
- IBRX Stock Outlook After Q1 Results and a New FDA ReviewNasdaqAGEN, IOVA, IBRX
- ImmunityBio: Anktiva Explained and What Comes NextNasdaqAGEN, IOVA, IBRX
Agenus peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| KYTXKyverna Therapeutics Inc. | 4.26 | -2.52% | $269.33M | vs AGEN |
| AGMBAgomAb Therapeutics NV ADR | 5.45 | -3.02% | $268.40M | vs AGEN |
| OCGNOcugen Inc. | 0.7679 | +4.79% | $260.55M | vs AGEN |
| DTILPrecision BioSciences Inc. | 7.40 | +7.09% | $282.46M | vs AGEN |
| EIKNEikon Therapeutics Inc. | 4.74 | -0.42% | $256.84M | vs AGEN |
| SABSSAB Biotherapeutics Inc. | 2.81 | -3.44% | $253.15M | vs AGEN |
| EDITEditas Medicine Inc. | 1.64 | -4.09% | $253.12M | vs AGEN |
| LXEOLexeo Therapeutics Inc. | 2.96 | +0.34% | $245.05M | vs AGEN |
Indexes, lists and sector
Agenus stock FAQ
What is Agenus's stock price today?
AGEN last traded at $5.97 as of Nov 20, 4:00 PM EST, down 2.77% on the day. Prices are delayed at least 15 minutes.
Does Agenus pay a dividend?
No. Agenus does not currently pay a regular cash dividend.
What is AGEN's P/E ratio?
AGEN trades at a trailing P/E ratio of 25.96.
Who is Agenus's CEO?
Dr. Garo H. Armen Ph.D. is the chief executive officer of Agenus Inc., which has about 81 employees.
Has AGEN ever split its stock?
Yes. The most recent AGEN stock split was a 1-for-20 split on Apr 12, 2024, one of 3 splits on record.
What is the AGEN 52-week high?
The 52-week high for AGEN is $10.31 and the 52-week low is $2.71. The stock is currently 42.1% below its high.